San Diego-based BioClarity, a skincare brand, has secured $13 million in funding. Prolog Ventures led the round.
1 min read · 15 May 2019
San Diego-based BioClarity, a skincare brand, has secured $13 million in funding. Prolog Ventures led the round.
1 min read · 15 May 2019
San Francisco-based Phil Inc, a technology platform for distributing and managing specialty prescription drugs, has raised $25 million in Series B funding. GreatPoint Ventures led the round with participation from Tarsadia Investments, Crosslink Capital and Uncork Capital.
1 min read · 15 May 2019
Phoenix-based Solera Health, a health network, has secured $42 million in Series C funding. HCSC Ventures led the round.
1 min read · 15 May 2019
Phoenix-based Solera Health, a health network, has secured $42 million in Series C funding. HCSC Ventures led the round.
1 min read · 15 May 2019
Seattle-based Karat, which conducts technical interviews on behalf of companies, has raised $28 million in Series B funding. Tiger Global Management led the round with participation from return backers Norwest Venture Partners and 8VC.
1 min read · 15 May 2019
Seattle-based Karat, which conducts technical interviews on behalf of companies, has raised $28 million in Series B funding. Tiger Global Management led the round with participation from return backers Norwest Venture Partners and 8VC.
1 min read · 15 May 2019
Brooklyn, New York-based Zipari, an insurance software startup, has named Mark Poling as chief product officer. Zipari is backed by Vertical Venture Partners.
2 min read · 15 May 2019
Menlo Park, California-based Phathom Pharmaceuticals, a newly launched biopharmaceutical company focused on treating gastrointestinal diseases and disorders, has secured $90 million in funding. Frazier Healthcare Partners led the round with participation from other investors that included Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen. Also, Phathom has secured a $50 million term loan facility from Silicon Valley Bank.
5 min read · 15 May 2019
Menlo Park, California-based Phathom Pharmaceuticals, a newly launched biopharmaceutical company focused on treating gastrointestinal diseases and disorders, has secured $90 million in funding. Frazier Healthcare Partners led the round with participation from other investors that included Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors, BVF Partners LP, Greenspring Associates, Richard King Mellon Foundation and Sahsen. Also, Phathom has secured a $50 million term loan facility from Silicon Valley Bank.
5 min read · 15 May 2019
